10 Healthcare Stocks with A+ EPS Revision Ratings Attracting Investor Attention
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy CAH?
Source: seekingalpha
- EPS Rating Upgrade: Ten healthcare stocks have received the highest A+ EPS revision rating from analysts, indicating increased confidence in their profitability outlook, which may attract more investor interest.
- List of Companies: Companies such as Cardinal Health (CAH) and HCA Healthcare (HCA) have achieved A+ ratings, showcasing strong earnings expectations that could drive their stock prices higher.
- Market Reaction: As analysts revise their earnings estimates upward for these companies, investors may reassess their portfolios, thereby increasing overall market attention on healthcare stocks.
- Industry Trends: With the earnings season underway, the robust performance of healthcare stocks and positive analyst revisions may signal a sector recovery, further attracting capital inflows into this area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 222.280
Low
209.00
Averages
225.18
High
244.00
Current: 222.280
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Escalating Middle East Conflict: The U.S. and Israel's bombing of Iran has pressured global stocks, with the S&P 500 dropping 2% last week, while oil prices surged to $90 per barrel, marking a 35% weekly gain, the largest since 1983, indicating potential economic repercussions.
- Mixed Economic Data: Although the ADP report indicated a rise of 63,000 private sector jobs in February, surpassing expectations, the subsequent nonfarm payroll report revealed an increase in the unemployment rate to 4.4%, highlighting emerging job losses due to AI and creating uncertainty about the economic outlook.
- Earnings Impact: Broadcom exceeded earnings expectations, resulting in a 3.4% stock increase, while Corning's shares fell nearly 7% following comments from Broadcom's CEO that dampened optimism about fiber-optic technology, reflecting market volatility in tech sectors.
- Investment Strategy Adjustments: Amid market fluctuations, the investment club increased its position in Cardinal Health and exited BlackRock entirely due to rising private credit concerns, demonstrating a proactive approach to navigating the current market landscape.
See More
- Market Reaction: The S&P 500 and Nasdaq both fell about 1% on Friday due to escalating tensions in the Middle East, reflecting increased investor uncertainty, particularly after President Trump stated there would be no deal with Iran.
- Rising Oil Prices: Oil prices reached their highest levels since April 2024, causing U.S. gas prices to rise, which benefits Costco as its reputation for low gas prices attracts more customers, leading to a 1% increase in its stock price on Friday.
- Financial Sector Pressure: Financial stocks continue to face pressure as a spike in private credit redemptions weighs on sentiment, with shares of Goldman Sachs, Capital One, and Wells Fargo declining, while BlackRock's stock dropped nearly 6% after it limited withdrawals from a private credit fund, raising concerns about financial health.
- Investment Strategy: During Friday's meeting, Jim Cramer highlighted that despite the market's downturn, there are still buying opportunities, particularly favoring Goldman Sachs and Cardinal Health, the latter of which saw its fourth purchase this week.
See More
- Share Acquisition: Jim Cramer's Charitable Trust purchased 50 shares of Cardinal Health at approximately $217.84, increasing its total holdings to 400 shares and raising its weighting from 2% to 2.25%, demonstrating ongoing confidence in the company.
- Market Performance Insight: Despite a broader market downturn, Cardinal Health's shares have risen, reflecting market trust in its resilience against rising oil prices and geopolitical tensions, indicating strong fundamentals.
- Investment Strategy: Cramer emphasizes a gradual accumulation strategy to lower the average cost basis, avoiding the risks associated with large one-time purchases, a tactic that proves crucial amid current market volatility.
- Financial Sector Dynamics: The financial sector is the worst performer, impacted by rising oil prices and weak job data; although Goldman Sachs offers a 2% dividend yield, market volatility may hinder its anticipated M&A and IPO activities.
See More
- Increased Stake: We purchased 90 shares of Cardinal Health at approximately $217, raising our total holdings to 350 shares and increasing its weight from 1.46% to about 2%, demonstrating confidence in the company's future growth potential.
- Market Performance Analysis: Despite the healthcare sector's poor performance this week, Cardinal Health's stock drop is not tied to fundamentals, providing more upside to our $260 price target, reflecting a misunderstanding of the stock by the market.
- Industry Dynamics: The drug distribution sector is under pressure, particularly McKesson, which saw a 5% drop in shares following the announcement of its longtime CFO's retirement, indicating market sensitivity to leadership changes, even though this transition was planned.
- Investment Strategy: We are leveraging our ample cash position to increase our stake in Cardinal Health, replacing our exit from Danaher, which has fallen about 3% since last week, showcasing our ability to flexibly adjust our portfolio amid market fluctuations.
See More
- Market Response Strategy: Jim Cramer emphasizes a cautious approach during the market turmoil caused by the Iran war, avoiding panic selling to prevent missing out on potential rebounds, demonstrating a keen awareness of market dynamics.
- Trading Dynamics: The Investing Club's decision to increase its position in Cardinal Health while trimming BlackRock on Monday reflects a flexible portfolio adjustment strategy aimed at maintaining cash flow amidst market uncertainty.
- Alphabet Investment Strategy: The club's additional purchase of Alphabet shares below $300 showcases a strategy to lower the cost basis while expressing confidence in the company's AI leadership, utilizing a small-scale, incremental buying approach to navigate short-term market unpredictability.
- Nvidia Upgrade Decision: The club upgraded Nvidia's stock rating to buy based on its strong earnings report and positive forward guidance, anticipating significant product advancements at the upcoming GTC conference, highlighting the focus on growth potential in the AI sector.
See More
- BlackRock Exit: We sold 35 shares of BlackRock at approximately $1,050 each to address pressures in the private markets, acknowledging that while BlackRock's private markets business isn't its primary revenue driver, recent industry weakness could hinder broader adoption among retail investors.
- Cardinal Health Increase: We purchased 90 shares of Cardinal Health at roughly $224 each, increasing our holdings to 260 shares and raising its portfolio weight from 1% to 1.5%, aiming to enhance the portfolio's defensive posture amid rising inflation concerns.
- Market Impact: The net result of these trades is neutral to our cash position, with the overall portfolio weight slightly exceeding 15%, reflecting our view that the market pullback presents an opportunity to invest in economically resilient healthcare companies like Cardinal Health.
- Strategic Shift: By exiting BlackRock while simultaneously increasing our stake in Cardinal Health, we demonstrate a strategic pivot towards more defensive healthcare suppliers in response to potential economic challenges posed by rising energy prices and an aging U.S. population.
See More









